7 Hills Pharma
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2450 Holcombe Blvd Ste J, Houston, Texas...Phone Number
(346) 772-0374Website
www.7hillspharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About 7 Hills Pharma
7 Hills Pharma Inc. is a clinical-stage drug development company focused on advancing first-in-class integrin-targeted agonists to enhance the effectiveness of immunotherapies for cancer and stem cell transplantation. Their lead molecules, Alintegimod and 7HP935, aim to overcome resistance in solid tumors and improve cell-based therapies for acute leukemias and genetic disorders. The company is dedicated to making safe and effective cancer treatments accessible to all patients. With a team experienced in drug discovery and clinical development, 7 Hills Pharma is committed to transforming patient care through innovative solutions.Explore more
7 Hills Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is 7 Hills Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once 7 Hills Pharma has new funding data
7 Hills Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at 7 Hills Pharma
Click to see if 7 Hills Pharma had a recent Job posting/layoffs
Check if 7 Hills Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if 7 Hills Pharma is spiking on competitors!
Earning: See what the market has to say on 7 Hills Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when 7 Hills Pharma launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to 7 Hills Pharma
Compare insights from companies similar to 7 Hills Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
7 Hills Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
7 Hills Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about 7 Hills Pharma.
7 Hills Pharma Tech Stack
A closer look at the technologies used by 7 Hills Pharma
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Project
recevied an award of $928,224 on April 26, 2023 by HHS NIH with an award end date of March 31, 2025. This award will support efforts focused on evaluating 7HP349, an oral small-molecule ?4?1/?L?2 activator, as a novel adjuvant to enhance T cell responses and vaccine efficacy in the elderly, aiming to improve influenza vaccination outcomes.
Clinical Operations, Operations
Funding
Project
Laboratory Operations, Medical Research, Operations
Event
7 Hills Pharma News & Media
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349, its first-in-class oral selective integrin activator into a Phase 1b/2a clinical trial in patients who are resistant to PD-1-based therapies. The new CPRIT funds follow over $13MM in federal grant awards, in collaboration with world-class7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies
HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) has secured newly issued US patent claims that significantly expand the extent of the company’s intellectual property (IP) estate. By virtue of these new claims (issued patent no. 11,311,619), the 7HP IP estate now encompasses combinations of any integrin agonist with any antigen. Along with existing company IP broadly covering the landscape of small molecule integrin agonists, the new patentNew Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”), released a new study in The Journal of Clinical Investigation, describing the use of 7HP’s novel integrin activator 7HP349 to convert “cold” or non-immunogenic tumor microenvironments to a “hot,” T cell-enriched state, improving the effectiveness of immune checkpoint blockade. The article, entitled “L
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding 7 Hills Pharma
Sign Up For FreeTo access detailed company insights
7 Hills Pharma Inc. is a clinical-stage drug development company focused on advancing first-in-class integrin-targeted agonists to enhance the effectiveness of immunotherapies for cancer and stem cell transplantation. Their lead molecules, Alintegimod and 7HP935, aim to overcome resistance in solid tumors and improve cell-based therapies for acute... Read More
